Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 3/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | ABL2 | P42684 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106586 | 0.95 | KDM1A (0.36) | KDM1ASRCCCNB2CDK1CCNB1 | |
| SCHEMBL10172437 | 0.81 | CCNB2 (0.35) | KDM1ACCNB2CDK1CCNB1GSK3B | |
| SCHEMBL2533961 | 0.81 | MCHR1 (0.32) | SRCCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL17993515 | 0.79 | CCNB2 (0.33) | KDM1ACCNB2CDK1CCNB1GSK3B | |
| SCHEMBL21383117 | 0.78 | MST1R (0.37) | KDM1A | |
| SCHEMBL171849 | 0.77 | ADRA2B (0.32) | — | |
| SCHEMBL21385824 | 0.77 | MST1R (0.39) | KDM1AABL1 | |
| SCHEMBL17993507 | 0.77 | ADRA2B (0.32) | — | |
| SCHEMBL28574670 | 0.75 | SRC (0.32) | SRC | |
| SCHEMBL1478907 | 0.75 | MCHR1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| WO-2009109035-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | PTK2B, PRKACA, DSTYK | KDM1A 1502/4885SRC 40/4885CCNB2 1702/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | KDM1A 1061/4885SRC 436/4885CCNB2 1407/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | KDM1A 1609/4885SRC 14/4885CCNB2 1840/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | KDM1A 1609/4885SRC 14/4885CCNB2 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.